Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Initiates $2M Private Placement

NEW YORK (GenomeWeb) – Rosetta Genomics said today that it has entered into a definitive agreement with an institutional healthcare investor for a $2 million private placement.

Under the terms of the agreement, Rosetta will issue unregistered convertible debentures (convertible into approximately 2.2 million ordinary shares) and warrants to purchase up to the same number of ordinary shares for gross proceeds of $2 million.

The convertible debentures will have a term of 30 years, be unsecured, not bear any interest, and have a conversion price of $0.92 per share.  The warrants will have a term of five years, be exercisable upon issuance, and have an exercise price of $1.15 per share.

The closing of the offering is expected to occur on or about Oct. 2 subject to the satisfaction of customary closing conditions, Rosetta said. The company did not disclose its intended use for the proceeds.

Earlier this month Rosetta said it was implementing a cost-reduction plan to initially trim its annual operating expenses by $1.7 million, primarily through layoffs and discretionary spending cuts. The company also recently agreed to sell its PersonalizeDx molecular diagnostics unit to healthcare business group Pragmin Prognosis for $2.9 million in cash.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.